Romidepsin

Romidepsin
Clinical data
Trade names	Istodax
Other names	FK228; FR901228; Istodax
MedlinePlus	a610005
License data	US FDA: Romidepsin;
Routes of; administration	Intravenous infusion
ATC code	L01XH02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	Not applicable (IV only)
Protein binding	92–94%
Metabolism	Liver (mostly CYP3A4-mediated)
Elimination half-life	3 hours
Identifiers
	IUPAC name (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone;
CAS Number	128517-07-7 ;
PubChem CID	5352062;
IUPHAR/BPS	7006;
DrugBank	DB06176 ;
ChemSpider	10122002;
UNII	CX3T89XQBK;
ChEBI	CHEBI:61080 ;
ChEMBL	ChEMBL1213490 ;
CompTox Dashboard (EPA)	DTXSID8048579 ;
ECHA InfoCard	100.211.884
Chemical and physical data
Formula	C24H36N4O6S2
Molar mass	540.69 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C/C=C\1/C(=O)N[C@H](C(=O)O[C@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C;
	InChI InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1; Key:OHRURASPPZQGQM-GCCNXGTGSA-N;
	(what is this?) (verify)

Romidepsin, sold under the brand name Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis.^[2] It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs. Romidepsin is branded and owned by Gloucester Pharmaceuticals, a part of Celgene.^[3]

^ "Romidepsin-MSN, Romidepsin-Reach (Reach Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Archived from the original on 18 March 2023. Retrieved 29 April 2023.
^ Cite error: The named reference NCI was invoked but never defined (see the help page).
^ Cite error: The named reference Gloucester was invoked but never defined (see the help page).

[1] "Romidepsin-MSN, Romidepsin-Reach (Reach Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Archived from the original on 18 March 2023. Retrieved 29 April 2023.

[NCI-2] Cite error: The named reference NCI was invoked but never defined (see the help page).

[Gloucester-3] Cite error: The named reference Gloucester was invoked but never defined (see the help page).

[1]

[2]

[3]